

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer

Neurology® 2019;93:280. doi:10.1212/WNL.0000000000007380

In the article “Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer” by Touat et al.,¹ there were several errors published in the online ahead-of-print version on August 8, 2018. The corrected article was posted online on September 4, 2018.

- The legend for figure 1B should have included “Arrowheads indicate patients with both myocarditis and myositis” and should also have specified “myositis *associated with* immune checkpoint inhibitors” rather than “myositis induced by treatment with immune checkpoint inhibitors.”
- In figure 2G, the scalebar is 20 μm , rather than 50 μm , as originally published ahead-of-print.
- The table 1 legend should have noted “^aPerformance status at the time of ICI initiation” and reordered the following notes accordingly.
- In the Glossary, irMyositis should have been defined as “myositis *associated with* immune checkpoint inhibitors” rather than “myositis induced by immune checkpoint inhibitors,” as originally published. Further, PD-L1 and PD-L2 should have been defined as “programmed cell death 1 ligand 1” and “programmed cell death 1 ligand 2,” and PD-1 should have been defined as “programmed cell death protein 1.” In the ahead-of-print version, these 3 acronyms were incorrectly expanded as “programmed death-ligand 1,” “programmed death-ligand 2,” and “programmed death-1 receptor,” respectively. Lastly, CTLA-4 should have been defined as “cytotoxic T-lymphocyte associated protein 4” rather than “...T lymphocyte-associated antigen 4.”
- In the affiliations list, Dr. Timothée Lenglet was incorrectly listed with Service de Neurologie Raymond Escourolle rather than the Department de Neurophysiologie Clinique at Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix.
- In the author contributions section, Dr. Pauline Laly should have been listed as assisting with acquisition and interpretation of data, and critical revision of manuscript for intellectual content.
- In the Disclosure section, Dr. Touat’s statement should have read as follows (with changes italicized): “M. Touat is a consultant/advisory board member for Agios Pharmaceutical and Taiho Oncology and reports travel grants from Merck Sharp and Dohme, *outside the submitted work.*”

The publisher regrets these errors.

Reference

1. Touat M, Maisnobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. *Neurology* 2018;91:e985–e994.

Neurology[®]

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer

Neurology 2019;93;280

DOI 10.1212/WNL.00000000000007380

This information is current as of August 5, 2019

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/93/6/280.full
References	This article cites 1 articles, 1 of which you can access for free at: http://n.neurology.org/content/93/6/280.full#ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

